Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Med Insights Oncol. 2012;6:287-303. doi: 10.4137/CMO.S8511. Epub 2012 Aug 16.

Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.

Author information

  • 1College of Medicine, Penn State Hershey Medical Center, Hershey, PA, USA.

Abstract

Hormone ablation therapy (HALT) for breast or prostate cancer accelerates the development of osteoporosis in both men and women by causing estrogen deficiency, which increases the risk for fracture by promoting bone resorption mediated by osteoclasts. Denosumab, a fully human monoclonal antibody that inhibits osteoclast formation and function, increases bone mass in patients undergoing hormone ablation therapy. In the HALT study of 1,468 men with prostate cancer on androgen-deprivation therapy, denosumab significantly reduced the risk of new vertebral fractures, increased bone mineral density (BMD), and reduced markers of bone turnover. In a study of 252 women with breast cancer undergoing adjuvant aromatase inhibitor (AI) therapy, denosumab increased BMD at 12 and 24 months, overall and in all patient subgroups. The overall rates of adverse events were similar to placebo. Clinicians should consider fracture risk assessment and therapies such as denosumab to increase bone mass in patients on hormone ablation therapy who are at high risk for fracture.

KEYWORDS:

breast cancer; denosumab; hormone-ablation therapy; prostate cancer; treatment-induced bone loss

PMID:
22933844
[PubMed]
PMCID:
PMC3427033
Free PMC Article

Images from this publication.See all images (7)Free text

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Libertas Academica Icon for PubMed Central
    Loading ...
    Write to the Help Desk